Investors & Media

Immorna has successfully closed 3 rounds of financing with a total of 8 investors, including leading venture capitals and industry investors.

We welcome new investors. For investment
opportunities, please contact ir@immornabio.com
News Flow

News Update
Immorna’s mRNA Quadrivalent Seasonal Influenza Vaccine Obtains US. FDA IND Clearance

US. Eastern Time, July 27 2023, Immorna Biotherapeutics, Inc ("Immorna") announces that i...
2023.07

News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles

MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company f...
2023.05

News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology compan...
2023.01

News Update
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine

MORRISVILLE, N.C., November 21st, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology co...
2022.11

Immorna Receives IND Clearance to Conduct FIH Study of JCXH-211, the First-in-Class Self-replicating mRNA

Encoding Human IL-12 Protein, in Cancer PatientsRALEIGH, N.C., March 28, 2022 /PRNewswire/ -- Immor...
2022.03